学術論文

外国語文

1. Urakami S, Ogawa K, Oka S, Hagiwara K, Nagamoto S, Anjiki H, Hayashida M, Yano A, Sakaguchi K, Kurosawa K, Okaneya T. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin.
Low Urin Tract Symptoms. 2018 Sep 24.

2. Oka S, Inoshita N, Miura Y, Oki R, Miyama Y, Nagamoto S, Ogawa K, Sakaguchi K, Kondoh C, Kurosawa K, Urakami S, Takano T, Okaneya T. The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.
Urol Oncol. 2018 Aug;36(8):365.e9-365.e14.

3. Yuasa T, Urakami S, Yonese J. Recent advances in medical therapy for metastatic urothelial cancer.
Int J Clin Oncol. 2018 Aug;23(4):599-607.

4. Urakami S, Inoshita N, Oka S, Miyama Y, Nomura S, Arai M, Sakaguchi K, Kurosawa K, Okaneya T. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Int J Urol. 2018 Feb;25(2):151-156.

5. Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?
Ann Surg Oncol. 2017 Sep;24(9):2794-2800.

6. Ikeda M, Matsumoto K, Sakaguchi K, Ishii D, Tabata KI, Kurosawa K, Urakami S, Okaneya T, Iwamura M. Effect of Lymphadenectomy During Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma.
Clin Genitourin Cancer. 2017 Oct;15(5):556-562.

7. Miura Y, Inoshita N, Ikeda M, Miyama Y, Oki R, Oka S, Kondoh C, Ozaki Y, Tanabe Y, Kurosawa K, Urakami S, Kohno T, Okaneya T, Takano T. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
Urol Oncol. 2017 Jun;35(6):386-391.

8. Kurosawa K, Urakami S, Ishiwata K, Miyagawa J, Sakaguchi K, Fujioka M, Murata H, Inoshita N, Taniguchi S, Okaneya T. Significance of Urological Surgical Treatment for Viral Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation.
Hinyokika Kiyo. 2016 Nov;62(11):563-567.

9

. Tabata M, Urakami S, Takahashi S, Sakaguchi K, Ikeda M, Kurosawa K, Okaneya T, Homma Y. ACHIEVED REMARKABLE IMPROVEMENTS IN PERFORMANCE STATUS WHEN TREATED WITH COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND DOCETAXEL.
Nihon Hinyokika Gakkai Zasshi. 2016;107(4):256-260.

10. Kurosawa K, Urakami S, Ikeda M, Tabata M, Murata H, Okaneya T. Clinicopathological Study and Treatment Outcome of Retroperitoneal Soft Tissue Sarcoma.
Hinyokika Kiyo. 2015 Nov;61(11):419-26.

11. Urakami S, Okaneya T. Editorial Comment to Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.
Int J Urol. 2016 Feb;23(2):158-9.

12. Tabata M, Ikeda M, Urakami S, Takahashi S, Sakaguchi K, Kurosawa K, Okaneya T. Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy.
Jpn J Clin Oncol. 2015 Oct;45(10):963-7.

13. Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T, Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K. Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
Urol Int. 2016;96(1):65-72.

14. Urakami S, Yuasa T, Yamamoto S, Sakura M, Tanaka H, Hayashi T, Uehara S, Inoue Y, Fujii Y, Masuda H, Fukui I, Yonese J. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Int J Clin Oncol. 2015 Dec;20(6):1171-8.

15. Yuasa T, Inoshita N, Tanaka H, Urakami S, Yamamoto S, Fujii Y, Masuda H, Fukui I, Ishikawa Y, Yonese J. Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.
Int J Clin Oncol. 2015 Dec;20(6):1198-202.

16. Yuasa T, Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J. Clinical outcome of patients with pancreatic metastases from renal cell cancer.
BMC Cancer. 2015 Feb 12;15:46.

17. Yamamoto S, Masuda H, Urakami S, Fujii Y, Sakamoto K, Kozuka T, Oguchi M, Fukui I, Yonese J. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy.
Urology. 2015 Feb;85(2):407-13.

18. Akiyoshi T, Ueno M, Ono R, Urakami S. Laparoscopic resection of sigmoid colon cancer involving the left ureter with reconstruction by ileal interposition.
Dis Colon Rectum. 2014 Oct;57(10):1241.

19. Tanaka H, Yuasa T, Fujii Y, Sakura M, Urakami S, Yamamoto S, Masuda H, Fukui I, Yonese J. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Chemotherapy. 2013;59(6):441-6.

20. Urakami S. Editorial comment from Dr Urakami to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
Int J Urol. 2014 Oct;21(10):990-1.

21. Yuasa T, Urakami S. Kidney cancer: decreased incidence of skeletal-related events in mRCC.
Nat Rev Urol. 2014 Apr;11(4):193-4.

22. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Kitsukawa S, Masuda H, Ishikawa Y, Kozuka T, Oguchi M, Kohno A, Fukui I. Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution.
Int J Clin Oncol. 2014 Dec;19(6):1085-91.

23. Yamamoto S, Fujii Y, Masuda H, Urakami S, Saito K, Kozuka T, Oguchi M, Fukui I, Yonese J. Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer.
Qual Life Res. 2014 Jun;23(5):1641-50.

24. Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Sakura M, Yuasa T, Kihara K, Fukui I. The processus vaginalis transection method to prevent postradical prostatectomy inguinal hernia: long-term results.
Urology. 2014 Jan;83(1):247-52.

25. Urakami S, Fujii Y, Yamamoto S, Yuasa T, Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
Urol Oncol. 2014 Jan;32(1):35.e1-7.

26. Yasuda Y, Yuasa T, Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Yonese J, Fukui I. Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer.
Urol Int. 2013;90(2):179-83.

27. Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers.
Onco Targets Ther. 2012;5:221-9

28. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma.
Int J Clin Oncol. 2012 Sep 11. [Epub ahead of print]

29. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Int J Clin Oncol. 2012 Aug 11. [Epub ahead of print]

30. Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J, Fukui I. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
BJU Int. 2012 Nov;110(10):1478-84.

31. Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A, Fukui I. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Jpn J Clin Oncol. 2012 Jun;42(6):541-7.

32. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Urology. 2011 Nov;78(5):1131-5.

33. Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int. 2012 May;109(9):1349-54.

34. Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I. Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml.
Urol Int. 2011;87(2):175-81.

35. I noue S, Shiina H, Arichi N, Mitsui Y, Hiraoka T, Wake K, Sumura M, Honda S, Yasumoto H, Urakami S, Matsubara A, Igawa M. Identification of lymphatic pathway involved in the spreading of prostate cancer by fluorescence navigation approach with intraoperatively injected indocyanine green.
Can Urol Assoc J. 2011 Aug;5(4):254-9.

36. Inoue S, Shiina H, Arichi N, Mitusi Y, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M. Rare complication of a sigmoid colon perforation after a kidney transplant with an artificial vascular graft.
Exp Clin Transplant. 2011 Jun;9(3):207-10.

37. Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K, Fukui I. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
Clin Exp Metastasis. 2011 Apr;28(4):405-11.

38. Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikwa Y, Fukui I. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Urology. 2011 Apr;77(4):831-5.

39. Inoue S, Shiina H, Sumura M, Urakami S, Matsubara A, Igawa M. Impact of a novel, extended approach of perineal radical prostatectomy on surgical margins in localized prostate cancer.
BJU Int. 2010 Jul;106(1):44-8.

40. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
Ann Oncol. 2010 Feb;21(2):312-8.

41. Kawakami T, Urakami S, Hirata H, Tanaka Y, Nakajima K, Enokida H, Shiina H, Ogishima T, Tokizane T, Kawamoto K, Miura K, Ishii N, Dahiya R. Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence.
Int J Impot Res. 2009 Nov-Dec;21(6):348-55.

42. Inoue S, Shiina H, Hiraoka T, Mitsui Y, Sumura M, Urakami S, Igawa M. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery.
BJU Int. 2009 Oct;104(8):1085-90.

43. Inoue S, Shiina H, Hiraoka T, Wake K, Sumura M, Honda S, Urakami S, Igawa M, Usui T. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures.
BJU Int. 2009 Oct;104(8):1077-84.

44. Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, Nunes L, Urakami S, Shiina H, Igawa M, Tanagho E, Dahiya R. Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.
BJU Int. 2009 May;103(10):1424-8.

45. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Int J Cancer. 2008 Aug 1;123(3):552-60.

46. Urakami S, Hiraoka T, Inoue S, Wake K, Kikuno N, Sumura M, Honda S, Shiina H, Ishikawa N, and Igawa M. Long-term control or possible cure? In stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade. Int Urol Nephrol. 2008;40(2):365-8.

47. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
Oncogene. 2007 Dec 6;26(55):7647-55.

48. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, WakeK, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Phase-II Study of Docetaxel, Estramustine phosphate, and Carboplatin in Patients with Hormone-refractory Prostate Cancer.
Eur Urology. 2007 May;51(5):1252-8.

49. Urakami S, Shiina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Nunes L, Igawa M, Dahiya R. Tanagho EA. Functional Immprovement in spinal cord injuty-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat.
W J Urology. 2007 Apr;25(2):207-13.

50. Kawamoto K, Okino ST, Place RF, Li LC, Enokida H, Urakami S, Hirata H, Kikuno N, Nakagawa M, Dahiya R. Epigenetic Modifications of RASSF1A Gene through chromatin remodeling in Prostate Cancer.
Clin Cancer Res. 2007 May 1;13(9):2541-8.

51. Kikuno N, Urakami S, Nakamura S, Shiina H, Igawa M. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
Int J Urol. 2007 Jan;14(1):82-4.

52. Tanaka Y, Hirata H, Chen Z, Kikuno N, Kawamoto K, Majid S, Tokizane T, Urakami S, Shiina H, Nakajima K, Rajvir D. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):92-7.

53. Urakami S, Shiina H, Enokida H, Hirata H, Kawakami T, Kawamoto K, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R. Wnt-antagonist family genes as biomarkers for diagnosis, staging and prognosis of renal cell carcinoma using tumor and serum DNA.
Clin Cancer Res. 2006 Dec 1;12(23):6989-97.

54. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. Small dsRNAs induce transcriptional activation in human cells.
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17337-42. Epub 2006 Nov 3.

55. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.

56. Okino ST, Pookot D, Li LC, Zhao H, Urakami S, Shiina H, Igawa M, Dahiya R. Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer.
Cancer Res. 2006 Aug 1;66(15):7420-8.

57. Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16.

58. Hirata H, Hinoda Y, Matsuyama H, Tanaka Y, Okayama N, Suehiro Y, Zhao H, Urakami S, Kawamoto K, Kawakami T, Igawa M, Naito K, Dahiya R. Polymorphisms of DNA repair genes are associated with renal cell carcinoma.
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1058-62. Epub 2006 Feb 17.

59. Tanaka Y, Sasaki M, Shiina H, Tokizane T, Deguchi M, Hirata H, Hinoda Y, Okayama N, Suehiro Y, Urakami S, Kawakami T, Kaneuchi M, Pookot D, Igawa M, Okuyama A, Ishii N, Dahiya R. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):238-44.

60. Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Clin Cancer Res. 2006 Jan 15;12(2):383-91.

61. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma.
Cancer. 2006 Jan 1;106(1):79-86.

62. Yoneda T, Adachi H, Urakami S, Kishi H, Shigeno K, Shiina H, Igawa M. Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population.
J Urol. 2005 Nov;174(5):1944-7.

63. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer.
Clin Cancer Res. 2005 Sep 15;11(18):6582-8.

64. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, Ogishima T, Okino ST, Li LC, Tanaka Y, Nonomura N, Okuyama A, Dahiya R. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
Clin Cancer Res. 2005 Aug 15;11(16):5793-801.

65. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, Fujime M, Kane CJ, Carroll PR, Igawa M, Dahiya R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer.
Oncogene. 2005 Oct 13;24(45):6765-72.

66. Youssif M, Shiina H, Urakami S, Gleason C, Nunes L, Igawa M, Enokida H, Tanagho EA, Dahiya R. Effect of vascular endothelial growth factor on regeneration of bladder acellular matrix graft: histologic and functional evaluation.
Urology. 2005 Jul;66(1):201-7.

67. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer.
Int J Cancer. 2005 Aug 20;116(2):174-81.

68. Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Cancer Res. 2005 Mar 15;65(6):2130-8.

69. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Urology. 2005 Mar;65(3):543-8.

70. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Clin Cancer Res. 2005 Feb 1;11(3):1028-36.

71. Breault JE, Shiina H, Igawa M, Ribeiro-Filho LA, Deguchi M, Enokida H, Urakami S, Terashima M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):557-64.

72. Kawakami T, Shiina H, Igawa M, Deguchi M, Nakajima K, Ogishima T, Tokizane T, Urakami S, Enokida H, Miura K, Ishii N, Kane CJ, Carroll PR, Dahiya R. Inactivation of the hMSH3 mismatch repair gene in bladder cancer.
Biochem Biophys Res Commun. 2004 Dec 17;325(3):934-42.

73. Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Cancer Res. 2004 Oct 15;64(20):7526-32.

74. Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
Cancer Res. 2004 Sep 1;64(17):5956-62.

75. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.
J Urol. 2004 May;171(5):1855-60.

76. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Terashima M. Decreased　survival of prostate cancer cells in vitro by combined treatment of heat and an antioxidant inhibitor diethyldithiocarbamate (DDC).
Exp Toxicol Pathol. 2003 Nov;55(4):251-6.

77. Honda S, Kobayashi T, Kajino K, Urakami S, Igawa M, Hino O. Ets protein Elf-1 bidirectionally suppresses transcriptional activities of the tumor suppressor Tsc2 gene and the repair-related Nth1 gene.
Mol Carcinog. 2003 Jul;37(3):122-9.

78. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27.
J Urol. 2003 Aug;170(2 Pt 1):601-4.

79. Kikuno N, Yoshino T, Urakami S, Shigeno K, Kishi H, Hata K, Shiina H, Igawa M. The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.
Anticancer Res. 2003 Mar-Apr;23(2B):1305-12.

80. Shiina H, Igawa M, Breault J, Ribeiro-Filho L, Pookot D, Urakami S, Terashima M, Deguchi M, Yamanaka M, Shirai M, Kaneuchi M, Kane CJ, Dahiya R. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
Clin Cancer Res. 2003 Jun;9(6):2121-32.

81. Yoneda T, Igawa M, Shiina H, Shigeno K, Urakami S. Postoperative morbidity, functional results and quality of life of patients following orthotopic neobladder reconstruction.
Int J Urol. 2003 Mar;10(3):119-25.

82. Shigeno K, Igawa M, Shiina H, Kishi H, Urakami S. Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer.
BJU Int. 2003 Feb;91(3):223-6.

83. Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.
J Urol. 2002 Dec;168(6):2444-50.

84. Kikuno N, Urakami S, Shigeno K, Kishi H, Shiina H, Igawa M. Traumatic rhabdomyolysis resulting from continuous compression in the exaggerated lithotomy position for radical perineal prostatectomy.
Int J Urol. 2002 Sep;9(9):521-4.

85. Urakami S, Igawa M, Shiina H, Shigeno K, Kikuno N, Yoshino T. Recurrent transitional cell carcinoma in a child with the Costello syndrome.
J Urol. 2002 Sep;168(3):1133-4.

86. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Shigeno K, Terashima M. Modulation of heat-induced cell death in PC-3 prostate cancer cells by the antioxidant inhibitor diethyldithiocarbamate.
BJU Int. 2002 Aug;90(3):317-25.

87. Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, Dahiya R. Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.
Cancer Res. 2001 Oct 1;61(19):7101-9.

88. Kikuno N, Urakami S, Shigeno K, Shiina H, Igawa M. Urachal carcinoma associated with increased carbohydrate antigen 19-9 and carcinoembryonic antigen.
J Urol. 2001 Aug;166(2):604.

89. Moriyama-Gonda N, Igawa M, Shiina H, Urakami S, Wada Y, Terashima M. Heat-induced cellular damage and tolerance in combination with adriamycin for the PC-3 prostate cancer cell line: relationships with cytotoxicity, reactive oxygen species and heat shock protein 70 expression.
Eur Urol. 2000 Aug;38(2):235-40.

90. Yagi H, Igawa M, Shiina H, Shigeno K, Yoneda T, Wada Y, Urakami S. Inverted papilloma of the urinary bladder in a girl.
Urol Int. 1999;63(4):258-60.

91. Urakami S, Igawa M, Shiina H, Shigeno K, Yoneda T, Yagi H. Congenital collateral urethral duplication in the frontal plane.
J Urol. 1999 Dec;162(6):2097-8.

92. Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, Wada Y, Honda S, Nagasaki M. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Oncology. 1999 Apr;56(3):239-47.

93. Satake N, Urakami S, Hirayama Y, Izumi K, Hino O. Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma.
Int J Cancer. 1998 Sep 11;77(6):895-900.

94. Wada Y, Igawa M, Shiina H, Shigeno K, Yokogi H, Urakami S, Yoneda T, Maruyama R. Comparison of chromosomal aberrations detected by fluorescence in situ hybridization with clinical parameters, DNA ploidy and Ki 67 expression in renal cell carcinoma.
Br J Cancer. 1998 Jun;77(11):2003-7.

95. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Quantitative analysis of argyrophilic nucleolar organizar regions in transitional cell carcinoma of the bladder using silver staining.
Surgical Reseach Communication. 1997;19:15-25.

96. Urakami S, Tsuchiya H, Orimoto K, Kobayashi T, Igawa M, Hino O. Overexpression of members of the AP-1 transcriptional factor family from an early stage of renal carcinogenesis and inhibition of cell growth by AP-1 gene antisense oligonucleotides in the Tsc2 gene mutant (Eker) rat model.
Biochem Biophys Res Commun. 1997 Dec 8;241(1):24-30.

97. Kobayashi T, Urakami S, Cheadle JP, Aspinwall R, Harris P, Sampson JR, Hino O. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog.
Mamm Genome. 1997 Aug;8(8):554-8.

98. Urakami S, Tokuzen R, Tsuda H, Igawa M, Hino O. Somatic mutation of the tuberous sclerosis (Tsc2) tumor suppressor gene in chemically induced rat renal carcinoma cell.
J Urol. 1997 Jul;158(1):275-8

99. Urakami S, Igawa M, Shirakawa H, Shiina H, Kawanishi M. Quantitative analysis of NM23 protein immunoreactivity in renal cell carcinoma using an image analyzer.
J Urol. 1997 May;157(5):1928-31.

100. Kobayashi T, Urakami S, Hirayama Y, Yamamoto T, Nishizawa M, Takahara T, Kubo Y, Hino O. Intragenic Tsc2 somatic mutations as Knudson's second hit in spontaneous and chemically induced renal carcinomas in the Eker rat model.
Jpn J Cancer Res. 1997 Mar;88(3):254-61.

101. Urakami S, Igawa M, Shiina H, Ishibe T.Urethral caruncle with coexistence of intestinal heterotopia. A case report.
Int Urol Nephrol. 1997;29(3):341-4.

102. Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T. Inverted papilloma of the urinary bladder: a case evaluated for malignant potential.
Int Urol Nephrol. 1997;29(2):181-7.

103. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma.
Eur Urol. 1997;31(1):73-80.

104. Hino O, Mitani H, Kobayashi T, Tsuchiya H, Orimoto K, Kikuchi Y, Urakami S, Yamamoto T, Kajino K. Pathophysiological features of hereditary cancer.Gann Monograph on Cancer Reseach. 1996;44:175-187.

105. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T, Kawanishi M. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Cancer. 1996 Oct 15;78(8):1762-74.

106. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
J Clin Pathol. 1996 May;49(5):395-9.

107. Shiina H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer.
Oncology. 1996 May-Jun;53(3):233-40.

108. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Br J Urol. 1996 Mar;77(3):358-62.

109. Igawa M, Urakami S, Shiina H, Ishibe T, Usui T, Chodak GW. Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy.

110. Igawa M, Urakami S, Shiina H, Ishibe T, Matsubara A, Kadena H, Usui T. Limitations of ureteroscopy in diagnosis of invasive upper tract urothelial cancer.
Urol Int. 1996;56(1):13-5.

111. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Comparison of ureteropelvic transitional cell carcinoma with bladder transitional cell carcinoma using an image analyzer.
Urol Int. 1996;56(3):163-8.

112. Igawa M, Urakami S, Shirakawa H, Yokogi H, Shiina H, Ishibe T, Matsubara A, Usui T. Renal pelvic cancer with pulmonary metastasis:report of a case with 5-year survival following resection of metastasis.
Shimane J Med Sci. 1995-199614:33-35.

113. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T. Neoadjuvant chemotherapy and badder preservation for invasive bladder cancer.
Shimane J Med Sci. 1995-199614:15-17.

114. Shiina H, Igawa M, Yagi H, Urakami S, Shirakawa H, Ishibe T. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
Eur Urol. 1996;30(1):80-8.

115. Igawa M, Urakami S, Shirakawa H, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T. Preliminary results of concurrent methotrexate, cisplatin and radiation treatment for locally advanced urothelial cancers.
Int Urol Nephrol. 1996;28(2):189-94.

116. Shiina H, Urakami S, Shirakawa H, Igawa M, Ishibe T, Usui T. Estramustine-binding protein in carcinoma and benign hyperplasia of the human prostate.
Eur Urol. 1996;29(1):106-10.

117. Shiina H, Urakami S, Shirakawa H, Shigeno K, Himeno Y, Mizutani M, Igawa M, Ishibe T. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Eur Urol. 1996;29(1):99-105.

118. Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T. Biological characteristics of inverted papilloma of the urinary bladder.
Br J Urol. 1996 Jan;77(1):55-60.

119. Igawa M, Urakami S, Shiina H, Ishibe T, Shirane T, Usui T, Chodak GW. Immunohistochemical evaluation of proliferating cell nuclear antigen, prostate-specific antigen and alpha 1-antichymotrypsin in human prostate cancer.
Br J Urol. 1996 Jan;77(1):107-12.

120. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Nuclear DNA content in transitional cell carcinoma of the bladder analyzed by a quontitative image analyzer.
Diagnostic Oncology. 1995;4:214-218

121. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M. Factors related to the outcome of M-VAC in 101 patients with advanced urothelial cancer.
Hiroshima J Med Sci. 1995 Dec;44(4):113-7.

122. Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Usui T, Moriyama H. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study.
Hiroshima J Med Sci. 1995 Dec;44(4):93-7.

123. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T. Immunohistochemical analysis of nm23 protein in transitional cell carcinoma of the bladder.
Br J Urol. 1995 Dec;76(6):708-13.

124. Igawa M, Urakami S, Shiina H, Ishibe T, Kadena H, Usui T. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
Br J Urol. 1995 Sep;76(3):321-4.

125. Igawa M, Urakami S, Shiina H, Kishi H, Himeno Y, Ishibe T, Kadena H, Usui T. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract.
Urol Int. 1995;55(2):74-7.